Use of rituximab to decrease panel-reactive antibodies.
Patients with pre-formed antibodies may be at increased risk of rejection after organ transplantation. In this report, we describe the use of rituximab to decrease the percentage of pre-formed antibodies in a pediatric heart transplant recipient.
Balfour
Ian C
IC
Division of Cardiology, Department of Pediatrics, St. Louis University Health Sciences Center, St. Louis, Missouri 63104, USA. balfoui@slu.edu
Fiore
Andrew
A
Graff
Ralph J
RJ
Knutsen
Alan P
AP
D000906:Antibodies / Q000187:drug effects* / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D006348:Cardiac Surgical Procedures; D002648:Child; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D006330:Heart Defects, Congenital / Q000601:surgery; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology; D008297:Male; D012086:Reoperation; D000069283:Rituximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D007155:Immunologic Factors; D000069283:Rituximab